Clinical trial
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
NCT00123825 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00123825 |
|---|---|
| Title | Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer |
| Official title | A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gallbladder Cancer, Biliary Tract Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Cisplatin |
| Enrollment | 30 |
| Start date | Jul 1, 2002 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jul 26, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: